Budesonide Nasal Spray
Brand names: Rhinocort Aqua, Benacort
Budesonide nasal spray is an intranasal corticosteroid used for the prevention and treatment of allergic and non-allergic rhinitis and as medical therapy for nasal polyps.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Budesonide is a glucocorticoid that suppresses inflammatory mediators in the nasal mucosa, reducing congestion, rhinorrhoea, sneezing and polyp-related obstruction with limited systemic exposure.
Prescribing in practice
- Local effects such as nasal dryness, irritation and epistaxis are common, and nasal septal perforation has been reported rarely, so correct spray technique aimed away from the septum is important.
- Maximum benefit in allergic rhinitis is achieved with regular continued use rather than occasional dosing, ideally started before the allergen season.
- Prolonged high-dose intranasal corticosteroid use, especially with other steroid routes, carries a small risk of systemic effects, and growth should be monitored in children on long-term treatment.
Monitoring
For long-term use review nasal mucosal health and symptom control, and monitor growth in children receiving prolonged therapy.
Counselling the patient
- Use every day as prescribed for best effect, even when symptoms are mild.
- Aim the spray slightly outward, away from the central wall of the nose.
- Report persistent nosebleeds or crusting.
Evidence & guidelines
Intranasal corticosteroids such as budesonide are first-line treatment for moderate-to-severe allergic rhinitis in NICE and allergy guidance.
Reference: ARIA Guidelines; BSACI Allergic Rhinitis Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Adult Upper Airway Obstruction (Stridor) · DAS 2015 unanticipated difficult airway; RCEM
- Epistaxis Management · ENT-UK / NICE
- Acute Otitis Media · NICE NG91 2018
- Tonsillitis and Sore Throat · NICE NG84 2018
- Benign Paroxysmal Positional Vertigo · NICE CG124 / AAO-HNS Guidelines
- Acute Rhinosinusitis · NICE NG79 2017 / EPOS 2020